Critical Care Alert – November 1, 2005
November 1, 2005
View Issues
-
Activated Protein C for Severe Sepsis and A Low Risk of Death
In 2001, the PROWESS trial of 1690 patients with severe sepsis1 demonstrated that a 96-hour infusion of activated protein C, or drotrecogin alfa (activated) (DrotAA, Xigris®) at 24 g/kg/h decreased mortality at 28 days from 30.8% to 24.4% (P = 0.005). -
How Long Should You Wait Before Removing a Chest Tube?
Standard teaching advocates placing a chest tube on water seal in patients with a prior hemothorax or pneumothorax and obtaining a chest radiograph (CXR) the following morning. -
Special Feature: Recombinant Factor VIIa in Hemorrhagic Shock and Massive Transfusion
Uncontrolled hemorrhage remains an important cause of death in the ICU. Patients with severe traumatic injuries, gastrointestinal hemorrhage, and ruptured abdominal aortic aneurisms are but a few examples of those who develop coagulopathy and hemorrhage that is not amenable to surgical control and may not respond to traditional approaches to blood product transfusion. -
Pharmacology Watch: Roche is Under Pressure Over Its Antiviral Drug Tamiflu
ACE Inhibitors or ARBs for Prediabetics?; Xigris is Approved for Severe Sepsis; ACE Inhibitors Inhibiting Aortic Valve Stenosis?; FDA Actions -
Clinical Briefs in Primary Care supplement